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Chikungunya is an arthropod-borne virus transmitted by Aedes mosquito bites. A viral
mutation  has allowed Aedes albopictus to become the preferred vector extending the geo-
graphic spread of the condition. The virus causes an acute febrile illness occasionally
followed by a chronic rheumatic condition causing severe impairment. The diagnosis is
usually conﬁrmed with serology. No speciﬁc treatment is currently available. This articleeywords:
hikungunya
lphavirus
pidemics
reviews the condition with emphasis on his dissemination in the Americas.
© 2015 Elsevier Editora Ltda. All rights reserved.
the West African lineage.hikungunya virus has disseminated widely and
utochthonous cases have already been reported in the
mericas. Although the disease tends to be self-limited, a
rippling chronic condition with severe joint compromise
an affect patients for weeks to months. Health practitioners
eed to be acquainted with the manifestations, diagnostic
ethods and treatment options for this formerly “exotic”
ondition.
gent
he Chikungunya virus (CHIKV) is an arthropod-borne virus
hat belongs to the family Togaviridae, genus Alphavirus. Its
enome is composed by a single stranded positive polarity
NA molecule. The genome codiﬁes four non-structural pro-
eins (NS P 1-4) and three structural proteins (C, E1 and C2).
∗ Corresponding author.
E-mail address: mmadariaga@nchmd.org (M. Madariaga).
ttp://dx.doi.org/10.1016/j.bjid.2015.10.004
413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.The virus gets destroyed by desiccation and by temperatures
above 58 ◦C.1 The alphavirus genus includes about 29 species,
seven of these viruses can causes joint disorders in humans
including CHIKV, O’nyong-nyong (Central Africa), Ross River
and Barmah Forest (Australia and the Paciﬁc), Semliki For-
est (Africa), Sindbis (Africa, Asia, Australia and Europe), and
Mayaro (South America and the French Guyana).2
There are three lineages of CHIKV with distinctive geno-
typic and antigenic characteristics. The virus isolated during
the 2004–2006 epidemics in the Indian Ocean belongs
to a distinct set within the largest phylogenetic group
East/Central/South African (ECSA). However the Asian lineage
is the one currently ravaging the Americas. The other group is
3CHIKV persists in nature using two cycles: a sylvatic cycle
affecting primates and mosquitoes and an urban cycle affect-
ing humans and mosquitoes (Fig. 1).
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Virus replication occurs following these steps:
- Early replication of RNA into mRNA  and translation of early
regulatory proteins
- Late replication of the RNA into mRNA  and translation of
late structural proteins
- Assembly of structural proteins and single stranded positive
RNA, and virion maturation.4
Vector
Although there is an ample range of Aedes species that trans-
mit  the disease in Africa5; in Asia and in the Indian Ocean the
main vectors of CHIKV are Aedes aegypti and Aedes albopictus.
A. albopictus has a wider geographical distribution, and can
survive in both rural and urban environments. Mosquito eggs
are quite resistant to dry seasons. A. albopictus also has a rel-
atively long life, lasting 4–8 weeks and has a ﬂying range of
400–600 m.6 All these capabilities have allowed A. albopictus
to become an important vector not only of CHIKV, but also
of dengue and other arbovirosis. A comparison between A.
aegypti and A. albopictus is presented in Table 1.
In Brazil, an extensive DDT campaign eradicated A. aegypti
from the country in the 1940–50s, however the vector was rein-
troduced in 1970 and become widespread again. Since 1986 it
has been considered endemic in several major Brazilian cities.
A. albopictus invaded Brazil in the 1980s and a recent survey
has detected it in at least 59% of the Brazilian municipalities
and in 24 of the 27 federal units7,8 A. aegypti affects predomi-
nantly tropical areas of Brazil (North, North-East and Central
regions) and is more  widespread, whereas A. albopictus is more
common in the cooler Southern areas of the country. Both vec-
tors combined put 99% of the population of Brazil at risk of
acquiring CHIKV.9 Fig. 2 shows the geographic distribution of
Chikungunya virus in the Americas.
In the United States, A. aegypti has been established for
more than 300 years and since 1985 the Southeast of the
United States has been invaded by A. albopictus,  with a range
extending from South Florida to Illinois.10
The adaptation of CHIKV to A. albopictus is a relatively
recent event. During the outbreak in the Indian Ocean in
Table 1 – Comparison between Aedes aegypti and Aedes
albopictus.
Vector Aedes aegypti Aedes albopictus
Local distribution Predominantly
an urban vector,
breeds close to
households, can
bite indoor or
outdoors
Predominantly a
rural vector,
breeds far from
households,
mostly an
outdoor biter
Global distribution Narrower global
distribution
Wider global
distribution
Tendency to bite
humans
Occasional Aggressive
Preferred source of
blood meals
Prefers humans Affects humans
and a variety of
vertebrates
Nickname Yellow fever
mosquito
Asian tiger
mosquito 0 1 6;2  0(1):91–98
2005–2006 the virus has acquired a mutation at residue 226
of the membrane fusion glycoprotein-1, which allows it to
infest A. albopictus.  This mutation is likely the cause of the
wide spread of the disease.11
Pathogenesis
CHIKV is transmitted predominantly by female mosquito
bites. Alternatively the disease can be transmitted vertically
from mother to fetus or theoretically by blood transfusion
(although no cases have been reported so far).
After the inoculation, the virus invades endothelial cells
and subcutaneous ﬁbroblasts and replicates in a limited fash-
ion. Circulating blood cells may be refractory to invasion. New
viruses are transported to local lymph nodes where they fur-
ther replicate. A signiﬁcant viremia which can reach up to
108 copies/mL then ensues.12 In the initial phases there is a
massive infection of monocyte-derived macrophages which
act as “Trojan horses” and transport the virus into target
organs including muscle, joints, the liver and the brain.13
The innate immune response is activated by the virus via
pattern recognition receptors. This triggers the production of
type I interferon and activates interferon-stimulated genes
which encode more  than 300 proteins, with crucial roles in the
host defense. In vitro studies have shown that CHIKV can be
highly suppressed when interferon / is added to cells prior
to infection.14
Flow cytometry showing CD8+ T lymphocyte response in
the early stages of the disease and a CD4+ T lymphocyte-
mediated response in the later stages, as well as production of
several pro-inﬂammatory cytokines are evidence of a subse-
quent adaptive immunity reaction.15 There is heterogeneity
in the cytokines expressed, reﬂecting the time of the illness
in which they are measured and the different genetic back-
grounds of the individuals affected. The persistence of a local
reservoir of infected monocytes in the joints may potentially
explain chronic arthritis in a subset of patients. Patients with
chronic joint disease may have high levels of interleukin 6 and
granulocyte macrophage colony-stimulating factor, but not of
tumor necrosis factor (TNF) or IL-1b (a pattern seen in other
inﬂammatory arthritides). Chronically affected patients also
have normal levels of hepatocyte growth factor and eotaxin,
as compared with recovered patients, suggesting an inability
of the former subjects to maintain an immune mechanism
associated with clinical recovery.16
Clinical  manifestations
The incubation period for CHIKV virus ranges between 1 and
12 days. The disease usually presents abruptly with high
fever, rash, back aches and myalgia. The febrile episode lasts
3–4 days. Occasionally there is a second febrile course last-
ing shortly. Arthralgia and arthritis are extremely common
and usually polyarticular and distal, with as many  as ten
joints involved. Both, small and large joints can be affected.
Symmetric inﬂammation is common, but unilateral compro-
mise is possible. The pain is intense and crippling, preventing
patients from sleeping and ambulating properly. Articular
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ymptoms subside within 1 to 3 weeks. Other manifesta-
ion include headache; photophobia; sore throat; abdominal
ain, diarrhea and vomiting; and cervical or generalized
ymphadenopathy.17
A morbilliform rash mostly non-pruritic, initially appearing
n the upper limbs is the most common cutaneous manifesta-
ion. The rash may evolve into a vesiculobullous and rarely a
urpuric exanthema, particularly in children. Hyperpigmen-
ation in the centrofacial area and intertriginous ulcers can
lso be seen.18
Traditionally CHIKV infection was not associated with
eurologic involvement, however cases of encephalitis,
eningitis, acute ﬂaccid paralysis and sensorineural hearing
oss have been described in the recent outbreaks. Among neu-
ologic symptoms, the most prevalent seem to be abnormal
ental status, headache, focal deﬁcits and seizures.19
Photophobia, retro-orbital pain and conjunctival effusion
r conjunctivitis are quite common in the acute phase of the
llness. Anterior uveitis is the most common serious ocular
resentation and can be associated with corneal precipitates
nd hypopyon. Less commonly, posterior uveitis, retinitis,
horoiditis and optic neuritis have been described.20
Hemorrhagic manifestations are rare; however gingiv-
rrhagia, epistaxis, hematemesis and melena have been
escribed in old case series.21 Abnormal bleeding, milder
han the one seen in dengue fever, has a predilection for
hildren.
A high percentage of pregnant women could be affected
y CHIKV (close to 50% in a cohort in the Reunion Island).
ymptoms at presentation do not differ from the general pop-
lation, except for the presence of epistaxis or gingivorrhagia
hich were seen in 9% of pregnant females. Pregnant women
ay require hospitalization to rule out other conditions but
he outcome of their pregnancies seem to be unaffected:
he number of cesarean sections, third trimester bleeding,
reterm births, still births, newborns with low weight or new-
orns with congenital malformations was no different when
ompared with uninfected women.22
Transplacental transmission is unlikely. Transmission from
other to fetus occurs exclusively at the time of delivery in the
etting of intrapartum maternal viremia.23 Affected neonates
evelop pain, prostration, fever and thrombocytopenia within
ew days after birth. Some of them may have encephalopathy
nd intracranial bleeding with prolonged sequela.24
In the majority of patients, symptoms abate after 1–3
eeks; however some patients evolve into a chronic con-
ition. Chronic manifestations may include monoarthritis,
ndifferentiated polyarthritis, joint involvement simulat-
ng rheumatoid arthritis (including fulﬁllment of American
cademy of Rheumatology criteria, positive rheumatoid
actor and characteristic erosions in the X-ray), tenosynovi-
is/enthesopathy, seronegative spondyloarthritis and/or back
ain.25,26 The most prominent joint swelling occurs in the
nkles and feet.27 The intensity of the pain is less severe, but
till signiﬁcant. Extra musculoskeletal manifestations such as
ash, alopecia, pruritus, ocular manifestations and Raynaud’s
28henomenon may also occur. The chronic illness takes a
oll on the well being of patients who score low in quality-
f-life indices. They may be unable to return to work because
f difﬁculties walking and handling objects.28–30 There is 1 6;2  0(1):91–98 93
evidence that patients remain symptomatic 18–36 months and
even longer after becoming infected.27,29
Patients with more  prominent acute symptoms have
higher risk to evolve into the chronic stage: high fevers and
chills, severe malaise, notable polyarthralgia and generalized
myalgia and rash may be predictors of poor outcome.25 Other
risk factors for relapsing or persistent CHIKV infection include
age older than 45, higher titers of CHIKV antibodies and ele-
vated viral load.24,29 Also individuals with prior joint disease
are at risk: exacerbation of psoriatic and seronegative arthri-
tides in the setting of CHIKV infection have been described.25
It is likely that persistence of viral replication in synovial
ﬂuid is the cause of chronic manifestations as determined by
detection of viral RNA and antigen in the ﬂuid, and by persis-
tent serum elevation of IgM antibodies.31
Although CHIKV disease has been considered self-limited,
serious complications have been described as above, in addi-
tion lethality can also occur, particularly among the young, the
elderly, and the immunocompromised. In Ahmedabad, India
during an outbreak in 2006, all cause mortality was increased
during the months of August–November, which coincided
with the peak of the epidemic.32
In the other end of the spectrum, seropositive patients
without clinical manifestations have also been identiﬁed.
Cases of dengue (including the hemorrhagic presentation)
and CHIKV coinfection have been described (as they share the
same vector) however no coinfection with yellow fever has
been reported yet.
Epidemiology
CHIKV is an enzootic virus ﬁrst isolated in a febrile patient
during an outbreak in the Makonde Plateau in Tanzania in
1952.33 Since then cases have been reported from tropical and
subtropical regions of Africa, the Indian Ocean islands and
South and Southeast Asia, usually following a pattern with
outbreaks occurring every 7–20 years. The largest epidemic
of CHIKV occurred in 2005–2006 in the Reunion Island: about
266,000 residents of this island in the Indic Ocean (34.3% of
the population) were affected. Additionally as the Island is an
overseas department, many  cases were exported to France.28
In 2006 CHIKV reached continental India. The infection ini-
tially affected seven states but in the last report in 2010 had
extended to 18 States and territories in the Union.34 Several
other countries in South East Asia have reported cases since
then and CHIKV is widespread in Malaysia, Sri Lanka and
Indonesia.35
In 2007 an outbreak was reported in Ravenna, Italy causing
about 100 cases and at least one lethality, triggering efforts
by the European Centre for Disease Prevention and Control to
maintain vector control capabilities and respond effectively to
the emergent outbreak.36
In December 2013 the World Health Organization reported
the ﬁrst local transmission of CHIKV in the Americas in
the Caribbean island of Saint Martin.37 Reports of the dis-
ease ravaging other countries of South and Central America
have ensued since then. Although cases in returning travelers
were previously identiﬁed, the CDC described autochthonous
cases in Florida in 2014. A climate based mosquito population
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dynamics stochastic model predicts that areas with marked
season variation may become epidemic foci and potential tar-
gets for strategic vector control.38 It has been proposed that,
because individuals in the US spend far less time outdoors and
typically have door and window screens, and air conditioning,
the extend of a potential epidemics in the United States will
be less vast than in other countries.39
The ﬁrst autochthonous cases of CHIKV in Brazil were con-
ﬁrmed in Oiapoque, Amapa State, on September 13, 2014.
An epidemiological and clinical analyses of CHIKV infection
occurring in Brazil between April and September of 2014, sur-
prisingly detected in addition to the Asian lineage, several
cases of the ECSA lineage in Feira de Santana, Northeast Brazil.
The cases reported had not acquired the A226V mutation,
but there is concern that this genetic event may occur in the
future.9
Like any other vector transmitted disease the propagation
of CHIKV depends on characteristics of the vector, the host
and the environment.
Thanks to commercial exchange, A. albopictus has
expanded to new geographic areas including more  recently the
Southeast of the United States and the Caribbean region.40 As
mentioned previously, the A226V mutation has increased the
ﬁtness of CHIKV and its ability to replicate in A. albopictus.41
The climatic changes in Europe (and in the rest of the world)
have favored the propagation of A. albopictus and in some cases
the autochthonous transmission of CHIKV, such in Northern
Italy in 2007 (but also cases of dengue in the south of France
and in Croatia).32
Historically CHIKV infection was considered a self-limited
and non-lethal disease, however 254 deaths in Reunion were
attributed directly or indirectly to CHIKV, thus changing
the perspective about the infection and emphasizing the
role of the condition of the host in the prognosis of the
disease.32
Diagnosis
The laboratory diagnosis of CHIKV depends on the quality,
volume and timing of the sample obtained during the course
of the disease.42 CHIKV infection can be diagnosed and con-
ﬁrmed by direct detection of the virus, viral RNA recognition
or identiﬁcation of serum speciﬁc antibodies.43
An acute phase serum sample obtained within 7 days of
disease onset would likely have a high degree of viremia. This
sample will be the best diagnostic option for virus isolation
or nucleic acid detection.44 Both techniques are highly sen-
sitive and speciﬁc, and results can be obtained within hours
(for nucleic acid detection) or in 2 days (virus isolation).45 PCR
techniques have the advantage of being faster and provide
a prompt indication of the viral load in clinical samples
and in the supernatant of cultures42,43,46 whereas viral iso-
lation by means of cellular culture are slower and require a
biosafety level 3 laboratory to reduce the risk of viral trans-
mission. CHIKV isolation can be accomplished by intracerebral
46inoculation in mice less than a year old or by inocula-
tion in mosquitoes. In vitro cellular culture methods require
mosquito cells (C6/36) or other mammal  cells including BHK-
21, Vero and HeLa. The cytopathic effect the virus causes 0 1 6;2  0(1):91–98
in these cell lines has a sensitivity comparable to in vivo
methods.47
Most commonly the diagnosis of CHIKV is based on the
detection of anti-CHIKV IgM o IgG in acute and convalescent
samples. The diagnosis is conﬁrmed by a four-fold rising titer
between the aforementioned samples or by demonstration of
speciﬁc IgM antibodies.42,43 Speciﬁc IgM antibodies are readily
detected by enzyme linked immunosorbent assay (ELISA) 7
days post infection, thus making this test the preferred indi-
cator of recent infection. Many  patients may present too early
in the course of the disease and the test may need to be
repeated. Immunochromatography may be better for detec-
tion of IgG during the convalescent period. IgG antibodies
usually persists for years whereas IgM antibodies decline to
undetectable levels by 3 or 4 months, although in subjects
with chronic symptoms these antibodies may persist for up to
24 months.46
Treatment
Currently there is no speciﬁc therapy approved for CHIKV
disease. The only therapeutic option is symptomatic relief.
Hydration and electrolyte balance should be optimized. Para-
cetamol 1 g three to four times a day in adults; or 50–60 mg
per kg body weight per day in divided doses in children;
is the treatment of choice for fever, headache and/or pain
according to the World Health Organization.48 Other non-
steroidal analgesics are also usually recommended for pain
control; however aspirin should be avoided to prevent fur-
ther platelet dysfunction. In crippling cases corticosteroid use
has been advocated, although there is not enough scientiﬁc
information to support their use.49 French investigators who
have experienced the devastating outbreak in the Reunion
Island advocate use of tumor necrosis alpha inhibitors for
chronic cases that fulﬁll the criteria for rheumatoid arthritis
or seronegative spondyloarthropathy, but no supportive evi-
dence exists beyond expert advice.
Ribavirin is a purine nucleoside analog currently used in
the treatment of hepatitis C. A small study that enrolled 10
patients using ribavirin 200 mg  orally twice a day for 7 days
showed improvement in arthralgia and returned capacity to
ambulate. Unfortunately the study used non-blinded com-
parators and it was too small to reveal meaningful results.50 In
theory combined use of ribavirin and type I interferon alpha
may show a synergistic effect.
Chloroquine can inhibit viral replication in Vero cells by dis-
rupting internalization of CHIKV containing endosomes. An
open pilot study on 10 patients who completed 20 weeks of
therapy showed signiﬁcant improvement in the Ritchie artic-
ular index (commonly used to evaluate joint involvement in
patients with rheumatoid arthritis) and in morning stiffness,51
however a small clinical trial failed to show decrease in the
duration of viremia. Actually patients on chloroquine in that
trial complained or worsening arthralgia as compared with
placebo, but the course duration was only 5 days.52Anterior and posterior uveitis caused by CHIKV have been
treated with topical steroids and cycloplegics, and systemic
steroids and acyclovir respectively. The role of acyclovir in this
clinical situation is disputed.20
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Table 2 – Experimental drugs for the treatment of CHIKV
disease.
Drug Possible mechanism of action
Arbidol Inhibits CHIKV entry
6-Azauridine Inhibits viral genome
replication
Decanoyl-RVKR-
chloromethyl
ketone
Inhibits viral glycoprotein
maturation
5,7-Dihydroxyﬂavones Inhibits viral protein
translation
Harringtonine Inhibits viral protein
translation (speciﬁcally
production of nsP3 and E2
proteins)
Interferon alpha Immunomodulator
Mycophenolic acid Inhibits viral genome
replication
Peptide-conjugated
phosphorodiamidate
morpholino oligomer
(PPMO)
Inhibits  viral genome
replication
Phenotiazine Inhibits CHIKV entry
Polyinosinic
acid:polycytidylic acid
Immunomodulator
Small interfering RNA
(siRNA)
Inhibits  viral genome
replication
e
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countries), administered in a single injection and able to stim-Trigocherrines Inhibits viral protein
translation
There are a number of drugs which may potentially have
ffect against CHIKV but they have not been used in clini-
al trials.26,53 They are summarized in Table 2. Among them
iRNA, 21-23 nucleotide small interfering RNA that is homol-
gous in sequence to E2 and ns1 genes of Chikungunya, seem
o be highly promising.54
Human polyvalent immunoglobulins obtained from con-
alescent patients with CHIKV infection have been puriﬁed
nd used in mouse models and exhibit a high neutralizing
ctivity, preventing viremia.55 The use of hyperimmune serum
as been successfully explored in other viral diseases, but
o human trials have been attempted for CHIKV disease yet.
onoclonal antibodies have also been isolated and used as
Sklvatic CHIKV
transmission
cycle
Aedes furcifer,
Aedes africanus
Non - human primates
Aedes furcifer, Aedes africanus
Fig. 1 – Life cycle of the C 1 6;2  0(1):91–98 95
prophylactic agents in mice lacking type I IFN receptors. These
antibodies have shown complete protection against lethality
in the murine model.56
A case series has reported treatment for 21 patients with
chronic CHIKV infection who satisﬁed the American College
of Rheumatology criteria for rheumatoid arthritis (including
a positive rheumatoid factor). All patients were treated with
disease modifying antirheumatic drugs including methotrex-
ate and TNF blockers, in addition to corticosteroids. Overall
the clinical response seems to have been poor.57
Prevention
The best method to prevent CHIKV is avoidance of mosquito
bites. This may be accomplished by use of repellents (prefer-
ably containing DEET), wearing of long-sleeved shirts and long
pants and use of screens, bed nets and air conditioning.58
Reduction of peridomiciliary water puddles and containers
may prevent mosquito proliferation.
Travelers to endemic areas need to be educated about their
risks, precautions and symptom recognition.
There is potential of transmission of CHIKV via blood trans-
fusion, although cases have not been reported yet. Sanitary
authorities may need to undertake mass screening if the risk
is high.59
The OX513A strain of A. aegypti is composed by radiation
sterilized male insects. A study of the release of these agents
in a suburb of Juazeiro, Bahia, Brazil demonstrated a reduction
of 95% of the local A. aegypti population in one year. The Sterile
Insect Technique (SIT) is a genetic control system that seems
promising as a mean of vector control.60 Its use, among public
controversy, has been imitated in Key West, the most southern
region of the United States.
There is no vaccine currently available to prevent CHIKV
infection. An ideal vaccine, should be of low cost, highly sta-
ble (as it will be predominantly administered in developingulate rapid protection.
There are many  vaccine candidates that have been tested
in mouse models, one of the most intriguing ones is a
Humans,
other
vertebrates (?)
Aedes aegypti
Aedes albopictus
Aedes aegypti
Aedes albopictus
Urban CHIKV
transmission
cycle
hikungunya virus.
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Fig. 2 – Chikungunya in the Americas. In red: countries with endemic transmission with more  than 1000 cases reported. In
orange: Countries with endemic transmission with more  than 1000 cases reported. In blue: Countries or States with
imported cases only. Without color: Countries or States with no transmission reported.
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on-adjuvanted, inactivated whole virus CHIKV vaccine
pplied by dermal application using a delivery system called
oroderm. Foroderm consists of elongated microparticles to
hich the whole virus is attached. Topical application in mice
s followed by circulation of the particles into the lymphatic
ystem (veriﬁed by ﬂuorescence). A single application pro-
ected mice against viremia and disease following a virus
hallenge.61
In the last 2 years two vaccines have been tested in Phase
 trials in humans: a live recombinant measles-virus-based
hikungunya vaccine and a virus-like particle chikungunya
irus vaccine (VRC-CHKVLP059-00-VP). Both of them were
mmunogenic, safe and well tolerated.62,63 More  advanced
hase II/III trials are hampered by the sporadic nature of the
nfection, which makes planning and approval of clinical trials
uiet challenging.
A  single vaccine has been tested in phase II trials. This
as a serially passaged, plaque-puriﬁed live Chikungunya vac-
ine produced by the United States Army Medical Research
nstitute for Infectious Diseases (USAMRIID). The vaccine was
njected subcutaneously and compared in a double-blinded
andomized study with placebo. Ninety eight percent of recip-
ents developed neutralizing antibodies (which persisted in
0% of cases for more  than a year). The vaccine was safe
nd the only difference with placebo was more  frequent
rthalgia.64 Despite the promising results further clinical
evelopment was aborted in 2000 due to the lack of commer-
ial interest.
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